Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. Given that the Phase 2 trial of ADX-2191 showed significant improvement in retinal function, this could be seen as a positive development for Aldeyra Therapeutics and could potentially boost its stock price in the short term.